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Key Points
• PR-OS of cHL patients
has improved in recent
years, likely due to in-
corporation of novel
therapies and more ef-
fective use of allo-HCT.
• Future research should
focus on earlier inte-
gration of novel thera-




Patients with classic Hodgkin lymphoma (cHL) who relapse after autologous hematopoietic
cell transplantation (auto-HCT) historically have had poor outcomes. We hypothesized that,
post–auto-HCT relapse, overall survival (PR-OS) has improved in recent years as a result
of more widespread use of novel therapies and allogeneic HCT (allo-HCT). We conducted
a retrospective study in 4 US academic centers, evaluating 215 patients who underwent auto-
HCT from 2005 to 2016 and relapsed thereafter. Patients were divided into 2 cohorts based
on timing of auto-HCT, 2005 through 2010 (cohort 1; n5 118) and 2011 to 2016 (cohort 2; n5 97),
to compare differences in clinical outcomes. The median age and disease status at auto-HCT
were similar in cohorts 1 and 2. The proportions of patients who received brentuximab vedotin
(Bv; 55% vs 69%; P5 .07), checkpoint inhibitors (CPIs; 3% vs 36%; P# .001), and allogeneic-HCT
(22% vs 35%, P5 .03) were significantly different between cohorts 1 and 2, respectively. At the
5-year follow-up after auto relapse, 32% and 50% of patients were alive in cohorts 1 and 2,
respectively (P5 .01). In multivariate analysis for PR-OS, cohort 1 vs 2 (hazard ratio [HR], 2.3;
95% confidence interval [CI], 1.14-4.60; P 5 .01), age at auto-HCT (HR, 1.48; 95% CI, 1.18-1.87;
P # .001), and time to relapse from auto-HCT (HR, 0.59; 95% CI, 0.47-74; P # .0001), retained
independent prognostic significance for PR-OS. Our study supports the hypothesis that
survival of cHL patients after auto-HCT failure has significantly improved in recent years,
most likely because of incorporation of novel therapies andmore widespread use of allo-HCT.
Introduction
Classic Hodgkin lymphoma (cHL) is a highly curable disease; however, 10% of patients with limited-stage
disease and 20% to 30% of patients with advanced-stage disease still experience failure of first-line
treatment.1,2 Autologous hematopoietic cell transplantation (auto-HCT) is the standard of care for patients
who do not achieve remission with first-line therapy, or who relapse after induction chemotherapy.3-5 Auto-
HCT provides durable remission in 30% to 70% of patients, depending on remission status before
transplant. Therefore, ;50% of cHL patients will ultimately relapse after auto-HCT. These patients
historically have had poor outcomes, with median survival in the 1.5-year range, without a significant
improvement in patients undergoing auto-HCT from 2000 through 2007 vs 1990 through 2000.6 A
small proportion of such cHL patients may eventually undergo allogeneic HCT (allo-HCT) and then
achieve long-term remission.7-9 For the remainder, disease control is the goal. In recent years, there
have been important new innovations in cHL treatment, including brentuximab vedotin (Bv) and checkpoint
inhibitors (CPIs), such as nivolumab and pembrolizumab.10-12 These agents have been shown to have high
response rates in patients with relapsed refractory cHL. In the case of Bv, a subgroup may in fact be
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cured.13 In addition to Bv and the PD-1 inhibitors, several other novel
agents are being evaluated for cHL and may contribute to improved
survival after auto-HCT failure.
We have observed a trend of anecdotally reported improved survival in
cHL patients after auto-HCT failure in recent years. This observation
led us to hypothesize that patients are living longer after auto-HCT
failure, because of the availability of several new and novel therapies.
To properly design trials for this group of patients, it will be important
to establish modern benchmarks of what the expected survival is
today with our current arsenal of available treatments. We therefore
conducted a multicenter retrospective study to evaluate survival
of cHL patients after the failure of an auto-HCT, comparing 2
different eras.
Methods
We conducted a multicenter retrospective study in 4 academic
institutions in the United States (Medical College of Wisconsin,
The Ohio State University, MD Anderson Cancer Center, and
Washington University in St. Louis) to evaluate survival of cHL
patients after the failure of an auto-HCT. For the purpose of
analysis, patients were divided into 2 cohorts based on the timing of
auto-HCT, 2005 to 2010 (cohort 1) and 2011 to 2016 (cohort 2), to
compare differences in treatment strategies and clinical outcomes.
We also sought to find post–auto-HCT-relapse survival and the
difference in survival between the 2 cohorts. Time to relapse was
defined as the time from auto-HCT to first documented evidence of
cHL relapse or progression. The documentation of relapse after auto-
HCT or after successive salvage therapies was determined by the
investigator at the participating center, supported by radiological and/
or histological confirmation. Overall survival (OS) was measured from
the date of relapse after auto-HCT to date of death or last follow-up.
This study was approved by the institutional review boards of all
4 centers.
Descriptive statistics were used to describe the patient population,
overall and as divided into the 2 cohorts. Univariate between-group
comparisons were performed using the Student t test, Wilcoxon
rank-sum test, or x2 test, as indicated depending on the variable
type. Overall survival was counted from the date of auto-HCT to
death and progression free-survival (PFS) was counted from auto-
HCT to disease progression or death. Patients alive without the
event of interest were censored at the last follow-up. Kaplan-Meier
estimates were used to visualize the survival experience of the
cohort and compared via the log-rank test. Left truncation was
used for analyzing survival from the time of auto-HCT, because the
patients did not enter the study cohort until the time of relapse or
progression. It was used to account for the variable timing of relapse
Table 1. Baseline characteristics
Variables Total (N 5 215) Cohort 1, 2005-2010 (n 5 118) Cohort 2, 2011-2016 (n 5 97) P
Age at diagnosis, median (range), y 32 (19-72) 32 (19-72) 32 (19-68) .59*
Age at auto-HCT, median (range), y 35 (19-73) 35 (20-73) 34 (19-71) .77*
Time from diagnosis to transplant, median (range), mo 18 (5-240) 21 (6-159) 16 (5-240) .03*
Time from transplant to relapse, median (range), mo 6 (1-103) 6 (1-103) 6.5 (1-59) .57*
Disease status before auto-HCT, n (%) .002*
CR 72 (34) 28 (24) 44 (45)
PR 121 (56) 76 (64) 45 (46)
SD 9 (4) 6 (5) 3 (3)
PD 13 (6) 8 (7) 5 (5)
ECOG PS at auto-HCT, n (%) .005†
0 55 (42) 32 (56) 23 (31.5)
1-2 75 (58) 25 (44) 50 (68.5)
Data missing 85 61 24
PET status before auto-HCT, n (%) .37†
Negative 81 (41.5) 41 (39) 40 (45)
Positive 114 (58.5) 65 (61) 49 (55)
Data missing 20 12 8
Best response after auto-HCT, n (%) .75*
CR 114 (53) 60 (51) 54 (56)
PR 39 (18) 29 (25) 10 (10)
SD 17 (8) 10 (8.5) 7 (7)
PD 44 (20.5) 19 (16) 25 (26)
Unknown 1 (0.5) 0 1 (1)
Postrelapse lines of therapy, median (range), n 2.0 (0.0-13.0) 2.0 (0.0-13.0) 2.0 (0.0-7.0) .07*
ECOG PS, Eastern Cooperative Oncology Group performance status.
*Wilcoxon rank-sum test.
†x2 test.
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or progression between patients. Multivariate Cox regression anal-
ysis was used to determine predictors of OS by cohort from the time
of auto-HCT relapse. Effect of Bv/CPIs and allo-HCT treatment after
auto-HCT relapse was analyzed as a time-dependent covariate, using
extended Kaplan Meier curves. These curves estimate the survival
experience of 2 hypothetical patients: 1 who received treatment
earliest and 1 who never got the intervention. The P value was based
on Mantel-Byar test. Patients with missing data were removed from
the analysis of the corresponding variables.
Results
Patient characteristics
Six hundred and fourteen patients who received auto-HCT from
2005 to 2016 were identified. Two hundred fifteen (35%) patients
relapsed after auto-HCT. Among those, 118 were from cohort 1
and 97 were from cohort 2. The median age at auto-HCT, time from
diagnosis to transplant, and time from transplant to relapse were
similar in cohorts 1 and 2 (Table 1). The disease status before
transplant, as assessed by CT, differed between the 2 cohorts, with
fewer patients in complete response (CR; 24% vs 45%) and more
patients in partial response (PR; 64% vs 46%) in cohort 1 than in
cohort 2, respectively (P 5 .002). However, as assessed by
positron emission tomographic (PET) scan in evaluable patients,
the disease status before transplant did not differ significantly
between the 2 cohorts: 39% vs 45%were PET negative in cohorts 1
and 2, respectively (P5 .37). The median number of lines of therapy
after relapse from auto-HCT were 2 each in cohorts 1 (range, 0-13)
and 2 (range, 0-7) (P 5 .07). Thirty-nine (55%) patients in cohort 1
and 59 (69%) patients in cohort 2 received Bv as a subsequent
therapy after auto-HCT (P5 .07). Similarly, 4 (3%) patients in cohort
1 vs 35 (36%) patients in cohort 2 received CPIs as a subsequent
therapy after auto-HCT relapse (P # .001; Table 2).
Survival outcomes
At a median follow-up of 5 years after auto-HCT relapse, 38% of
patients were alive in the entire group (Figure 1A): 32% in cohort 1
and 50.5% in cohort 2 (P 5 .01; Figure 1B). The proportion of
patients alive at 5-year follow-up from time of auto-HCT relapse,
using left truncation analysis was 30% and not reached in cohorts 1
and 2, respectively (P 5 .0076; Figure 1C). We then evaluated the
effect of time to relapse from auto-HCT (,1 year vs .1 year) on
postrelapse OS. The 5-year OS was 32% and 57% in patients
who relapsed in #1 year or .1 year from auto-HCT, respectively
(P 5 .003; Figure 1D).
In multivariate analysis for post–auto-HCT relapse overall survival
(OS), cohort 1 vs 2 (hazard ratio [HR], 2.3; 95% confidence interval
[CI], 1.14-4.60; P 5 .02), age at auto-HCT (HR, 1.48; 95% CI,
1.18-1.87; P # .001) time to relapse from auto-HCT (HR, 0.59;
95% CI, 0.47-74; P # .0001), progressive disease (PD) vs CR at
auto-HCT (HR, 2.86; 95% CI, 0.97-8.44; P 5 .05), and stable
disease (SD) vs CR (HR, 8.82; 95% CI, 1.06-73.3; P 5 .04)
retained independent prognostic significance for OS. Bv/CPI
treatment after auto-HCT (HR, 0.90; 95% CI, 0.49-1.67; P 5 .75)
or allo-HCT after auto-HCT relapse (HR, 0.86; 95%, CI; 0.42-1.67;
Table 2. Therapies after auto-HCT in 2 cohorts
Variables Cohort 1, 2005-2010 (n 5 118), n (%) Cohort 2, 2011-2016 (n 5 97), n (%) PTotal (N 5 215), n (%)
Anthracycline based (evaluable n 5 133) 31 (23) 17 (28) 14 (19) .25*
Gemcitabine based (evaluable n 5 145) 53 (37) 34 (47) 19 (26) .008*
Bv (evaluable n 5 157) 98 (62) 39 (55) 59 (69) .07*
CPIs 39 (18) 4 (3) 35 (36) ,.001*
Before allo-HCT 5 (8.5) 0 5 (14.7)
Clinical trial participation 71 (46) 42 (55) 29 (38) .02*
Data missing 62 42 20 .066* †
Allo-HCT performed 59 (28) 25 (22) 34 (35) .03*
Data missing 5 4 1
Type of allo-HCT .320* †
MRD 14 (24) 6 (24) 8 (23.5)
MUD 30 (51) 15 (60) 15 (44)
Haploidentical 8 (13) 1 (4) 7 (21)
Cord blood 7 (12) 3 (12) 4 (12)
Clinical outcome with allo-HCT
TRM at 100 d after allo-HCT 5 (8.5) 3 (12) 2 (6) .641* †
Complications related to allo-HCT .343* †
aGVHD 15 (25) 4 (16) 11 (32)
cGVHD 7 (12) 2 (8) 5 (15)
Infection 5 (8.5) 3 (12) 2 (6)
MRD, matched related donor; MUD, matched unrelated donor.
*x2 test.
†Fisher’s exact test.
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Figure 1. OS after post–auto-HCT relapse. Data were collected for the entire group (A); comparing cohorts 1 and 2 (B); comparing cohorts 1 and 2 using left truncation
(C); comparing time to relapse after auto-HCT, ,1 year vs .1 year (D); comparing patients who underwent allo-HCT or did not, as a time-dependent variable (E); and
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P 5 .67) as a time-dependent covariate did not show a significant
effect on OS in multivariate analysis (Figure 1E-F; Table 3).
Regimens given after auto-HCT relapse
Overall, 98 (45%) patients received Bv, with a median time from
relapse to Bv of 1.7 months (range, 0-98.5), overall response rate
(ORR) of 71% (CR rate, 32%), and median PFS of 7.3 months.
Thirty-nine (18%) patients received CPIs, with a median time from
relapse to CPI of 13.9 months (range, 0.4-114), ORR of 74% (CR
rate, 29%), and median PFS of 9.0 months. Overall, 5 (8.5%)
patients received CPIs before allo-HCT. All of these patients were
from cohort 2. Gemcitabine-based chemotherapy was administered
in 53 (25%) patients after auto-HCT relapse, with a median time
from relapse to gemcitabine of 8.8 months (range, 0.1-114), ORR
of 68% (CR rate, 20%), and median PFS of 4.5 months. Thirty-one
(14%) patients received an anthracycline-based regimen, with
a median time from relapse to anthracycline therapy of 7.7 months
(range, 0-79), ORR of 60% (CR rate of 17%), and median PFS of
4.6 months (Figure 2).
Allo-HCT after auto-HCT relapse
Fifty-nine (27%) patients received allo-HCT after auto-HCT relapse:
25 (22%) from cohort 1 and 34 (35%) from cohort 2 (P 5 .03).
Overall, 14 patients (24%) received matched related donor (n 5 6
[24%] cohort 1, n5 8 [24%] cohort 2), 30 patients (51%) received
matched unrelated donor (n 5 15 [60%] cohort 1; n 5 15 [44%]
cohort 2), 8 patients (14%) received haploidentical (n 5 1 [4%]
cohort 1; n 5 7 [21%] cohort 2) and 7 patients (12%) received
cord blood (n5 3 [12%] cohort 1; n5 4 [12%] cohort 2) allo-HCT.
Transplant-related mortality (TRM) within 100 days after allo-HCT
was observed in 3 (12%) and 2 (6%) patients from cohorts 1 and 2,
respectively (P 5 .64). Acute graft-versus-host disease (aGVHD)
was observed in 15 (25%) patients: 4 (16%) from cohort 1 and
11 (32%) from cohort 2. Chronic GVHD (cGVHD) was observed in
7 (12%) patients overall: 2 (8%) from cohort 1 and 5 (15%) from
cohort 2 (Table 2).
Median PFS after allo-HCT was 14.2 months (95% CI; 7.4 to not
reached; Figure 2E). After allo-HCT outcome as a time-dependent
covariate in multivariate analysis showed lower HR for mortality, but
it was not statistically significant (HR, 0.86; 95% CI, 0.42-1.67;
P 5 .67).
Of the 5 patients who received CPIs before allo-HCT, 2 had
aGVHD and 1 of those had TRM within 100 days of allo-HCT.
Median time from CPIs to allo-HCT was 1 month (range, 1-4.1).
One patient had disease progression 6.2 months after allo-HCT,
whereas the remaining patients were in remission at the time of
last follow-up.
Discussion
Our analysis supports our hypothesis that clinical outcomes for
cHL patients who relapse after auto-HCT have significantly improved
in recent years. This improvement is most likely related to the
integration of novel therapies and more accessibility of allo-HCT in
eligible patients, potentially in part because of the more widespread
application of haploidentical allo-HCT.
Historically, the outcome of cHL patients who relapse or progress
within a year of auto-HCT has been dismal, with median survival;1
to 1.5 years.6,14 In this group of patients, Bv in a phase II pivotal
study showed an objective response rate (ORR) of 75%, including
a CR rate of 34%.14 The median PFS observed was 6.5 months,
and 89% were alive at 1-year follow-up. These outcomes were
significantly better than those in traditional salvage chemotherapy
regimen trials given in the same era, such as the combination
regimen of gemcitabine, liposomal doxorubicin, and vinorelbine.15
Similarly, in our study, Bv given in the post–auto-HCT relapse
setting showed an ORR of 71% (CR; 32%) with a median PFS
of 7.3 months. Among the patients who received Bv, a larger
proportion were from cohort 2, likely contributing in part to the
improved outcome of cohort 2.
For patients who progress after auto-HCT and Bv, the outcome has
been poor, with a median survival of only 3.5 months in 1 study.16
cHL has a unique immune escape mechanism characterized by
amplification of 9p24.1 and consequent upregulation of PD-L1 and
-L2, making cHL particularly susceptible to CPIs such as the PD-1
inhibitors nivolumab and pembrolizumab.17 Nivolumab was tested in
a trial of 23 relapsed/refractory cHL patients, including 78% who
progressed after auto-HCT and Bv. In that study, nivolumab achieved
Table 3. Multivariate Cox regression analysis for cHL overall survival
Description Point estimate Lower 95% CI Upper 95% CI P
Cohort 1 vs cohort 2 2.300 1.148 4.606 .02
After Bv or CPI after relapse 0.908 0.492 1.679 .7594
After allo-HCT after relapse 0.860 0.426 1.738 .6742
Age at auto-HCT* 1.489 1.183 1.875 .0007
Time to relapse from auto-HCT† 0.596 0.474 0.749 ,.0001
ECOG PS at auto-HCT 1-2 vs 0 1.222 0.663 2.252 .5198
Disease status at auto-HCT
PD vs CR 2.862 0.970 8.445 .0569
PR vs CR 0.837 0.420 1.670 .6143
SD vs CR 8.822 1.062 73.308 .0439
ECOG PS, Eastern Cooperative Oncology Group performance status.
*Age was used as a continuous covariate. The coefficient for age is per each 10-year increase in age after relapse.
†Transplant-to-relapse time was used as a continuous covariate. The coefficient from transplant to relapse was per each doubling of the elapsed time.
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an ORR of 87% and a CR of 17%.11 Short-term PFS reported in that
study at the 24-week follow-up was 86%. In our study, 39 (18%)
patients received CPIs after auto-HCT relapse, with 90% being in
cohort 2. Most of these patients received CPIs relatively late, with the
median time from post–auto-HCT relapse to initiation of the drug
being 13.9 months. ORR observed with CPIs was 74% (CR 28%)
with median PFS of 9 months. Complementing previous studies, our
analysis from this multicenter collaboration in the real-world setting
demonstrates that immunemodulation via CPIs can improve outcomes
of poor-risk patients with multiply-relapsed or refractory cHL.
Historically, allo-HCT has been used as a treatment strategy in
patients with multiply-relapsed refractory cHL. However, the overall
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Figure 2. PFS after post–auto-HCT relapse. Data were collected after treatment with Bv (A), CPIs (B), gemcitabine-based chemotherapy regimens (C), anthracycline-
based chemotherapy regimens (D), allogeneic hematopoietic stem cell transplantation (E), and Bv and/or CPIs (F).
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in cHL continues to change. A recent meta-analysis concluded that
the outcome of allo-HCT for cHL has improved in recent years
because of better supportive care, the use of reduced-intensity
conditioning regimens, increased accessibility, and improved out-
come with alternative (haploidentical) transplantation.18 Further
supporting that notion, the Center for International Blood andMarrow
Transplant Research (CIBMTR) recently conducted a study focusing
on 596 patients who underwent a reduced intensity allo-HCT for HL
from 2008 through 2016. In that study, 3-year PFS was 34% to 38%
with a 1-year nonrelapse mortality (NRM) rate of 6% to 11%,
depending on donor source. Three-year OS was 63%, a dramatic
improvement compared with pre-2010 studies, in which NRM in
excess of 50% was reported in some series.19,20 In our study, we
found that a higher proportion of patients from cohort 2 (35%)
underwent allo-HCT compared with the number from cohort 1 (22%;
P 5 .03). Moreover, a higher proportion of patients from cohort 2
(21%) compared with the proportion from cohort 1 (4%) received
haploidentical allo-HCT. One can postulate that with the availability of
better salvage regimens and the use of haploidentical donors, more
patients respond and become eligible for allo-HCT.
However, at the same time that improved outcomes were seen
with allo-HCT, there appeared to be a shift toward decreased use of
allo-HCT for HL with the availability of Bv and CPIs. This finding is
illustrated by the relatively small proportion of patients proceeding
to allo-HCT after CPI treatment on the CheckMate 205 study with
nivolumab (18% of 243 patients) and the KEYNOTE-087 study with
pembrolizumab (4.8% of 219 patients).12,21 In addition, from 2012
through 2017, the number of cases of allo-HCT performed for HL in
the United States reported to the CIBMTR decreased by ;45%
(Marcelo Pasquini and Jeanette Carreras, CIBMTR, oral communi-
cation, 26 March 2019). This change may be related in part to
concerns about increased risk of severe GVHD when allo-HCT is
sequenced after CPI therapy, and/or to a perception that long-term
disease control after failure of auto-HCT can now be attained
without the use of allo-HCT, because of the availability of Bv, CPIs,
other novel agents and anti-CD30 chimeric antigen receptor
therapy. Although it is possible that this perception will eventually
prove to be true, studies with long-term follow-up have yet to
validate it, and caution should be exercised when advising against
a potentially curative option with a long track record (allo-HCT),
particularly in younger patients in whom NRM would be expected to
be low.
In subgroup analyses, we evaluated response rate and PFS with
novel therapies (Bv and CPIs) and chemotherapy (gemcitabine or
anthracycline)-based salvage regimens after auto-HCT relapse. We
observed better response rates (in the range of 70% to 75% vs
60% to 68%) and improved PFS (range, 7.0-9.0 months vs
4.5 months) with novel therapies compared with chemotherapy-
based salvage regimens, respectively. However, long-term disease
control was comparable with PFS of ;20% at 3-year follow-up
across all salvage regimens. Our analysis supports the notion that
for long-term disease control in high-risk cHL patients who progress
after auto-HCT, allo-HCT should continue to play a significant
role.22
We acknowledge the limitation of our retrospective analysis,
including the possibilities of inherent selection bias, incomplete
capture of all relevant data in 100% of patients, and limited follow-
up in small proportions of evaluated patients. A significant
proportion of patients had SD or PD before auto-HCT, which
one could argue may have contributed to an increased risk of
relapse; however, the proportion of patients with SD/PD were
comparable in the 2 cohorts. After adjusting for the disease status
at auto-HCT in the multivariate analysis, the inclusion of these
patients did not substantively affect the conclusions. A sensitivity
analysis removing those patients also did not qualitatively change
the estimated cohort effect.
In summary, the outcomes of cHL patients who experience relapse
after auto-HCT appear to have improved considerably in recent
years, owing to new treatment options (such as Bv and CPIs),
increased use of allo-HCT, and better supportive care. Future
research should focus on earlier integration of novel therapies for
patients with refractory disease to improve outcomes further.
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